Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression

Brain, Behavior, and Immunity

Volumn 31, Issue , 2013, Pages 205-215

  Mehta, Divya ^a   Raison, Charles L ^b,c,d   Woolwine, Bobbi J ^b   Haroon, Ebrahim ^b   Binder, Elisabeth B ^a,b   Miller, Andrew H ^b   Felger, Jennifer C ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d Environmental Research Laboratory   (United States)

Author keywords

Depression; Gene expression; Gluconeogenesis; Infliximab; Tumor necrosis factor

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR;

ADULT; APOPTOSIS; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SYMPTOM; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIDEPRESSIVE AGENTS; CARBOHYDRATE METABOLISM; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION PROFILING; GLUCOSE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878129547     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.04.004     Document Type: Article

References (66)

1. Andringa G., Lam K.Y., Chegary M., Wang X., Chase T.N., Bennett M.C. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 2004, 18(7):932-934.
2. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26(5):643-652.
3. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., Craig I.W., Anacker C., Zunsztain P.A., McGuffin P., et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38(3):377-385.
4. Cole S.W., Galic Z., Zack J.A. Controlling false-negative errors in microarray differential expression analysis: a PRIM approach. Bioinformatics 2003, 19(14):1808-1816.
5. Cole S.W., Hawkley L.C., Arevalo J.M., Cacioppo J.T. Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. Proc. Natl. Acad. Sci. USA 2011, 108(7):3080-3085.
6. Danese A., Moffitt T.E., Pariante C.M., Ambler A., Poulton R., Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch. Gen. Psychiatry 2008, 65(4):409-415.
7. Danese A., Pariante C.M., Caspi A., Taylor A., Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc. Natl. Acad. Sci. USA 2007, 104(4):1319-1324.
8. Dhabhar F.S., Burke H.M., Epel E.S., Mellon S.H., Rosser R., Reus V.I., Wolkowitz O.M. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J. Psychiatr Res. 2009, 43(11):962-969.
9. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67(5):446-457.
10. Eisenberger N.I., Berkman E.T., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 2010, 68(8):748-754.
11. Ekins S., Nikolsky Y., Bugrim A., Kirillov E., Nikolskaya T. Pathway mapping tools for analysis of high content data. Methods Mol. Biol. 2007, 356:319-350.
12. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(2):445-450.
13. Fagiolo U., Cossarizza A., Scala E., Fanales-Belasio E., Ortolani C., Cozzi E., Monti D., Franceschi C., Paganelli R. Increased cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol. 1993, 23(9):2375-2378.
14. Felger J.C., Cole S.W., Pace T.W., Hu F., Woolwine B.J., Doho G.H., Raison C.L., Miller A.H. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol. Med. 2011, 1-13.
15. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012, 33(3):315-327.
16. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV 1997, American Psychiatric Press, Washington DC.
17. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr Res. 1975, 12(3):189-198.
18. Godbout J.P., Johnson R.W. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol. Allergy Clin. North Am. 2009, 29(2):321-337.
19. Godbout J.P., Moreau M., Lestage J., Chen J., Sparkman N.L., Castanon N., Kelley K.W., Dantzer R., Johnson R.W. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008, 33(10):2341-2351.
20. Haider A.S., Cohen J., Fei J., Zaba L.C., Cardinale I., Toyoko K., Ott J., Krueger J.G. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J. Invest. Dermatol. 2008, 128(3):655-666.
21. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
22. Hansen S.K., Rose C.S., Glumer C., Drivsholm T., Borch-Johnsen K., Jorgensen T., Pedersen O., Hansen T. Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population. Diabetologia 2005, 48(3):452-458.
23. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37(1):137-162.
24. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66(5):407-414.
25. Hepgul N., Cattaneo A., Zunszain P.A., Pariante C.M. Depression pathogenesis and treatment: what can we learn from blood mRNA expression?. BMC Med. 2013, 11(1):28.
26. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009, 71(2):171-186.
27. Huber W., von Heydebreck A., Sultmann H., Poustka A., Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl. 1):S96-104.
28. Jahnsen F.L., Farkas L., Lund-Johansen F., Brandtzaeg P. Involvement of plasmacytoid dendritic cells in human diseases. Hum. Immunol. 2002, 63(12):1201-1205.
29. Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8(1):118-127.
30. Kim J.J., Mandelli L., Pae C.U., De Ronchi D., Jun T.Y., Lee C., Paik I.H., Patkar A.A., Steffens D., Serretti A., et al. Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(2):375-379.
31. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22(4):370-379.
32. Lequerre T., Gauthier-Jauneau A.C., Bansard C., Derambure C., Hiron M., Vittecoq O., Daveau M., Mejjad O., Daragon A., Tron F., et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res. Ther. 2006, 8(4):R105.
33. Maciver N.J., Jacobs S.R., Wieman H.L., Wofford J.A., Coloff J.L., Rathmell J.C. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J. Leukoc. Biol. 2008, 84(4):949-957.
34. Maddock C., Landau S., Barry K., Maulayah P., Hotopf M., Cleare A.J., Norris S., Pariante C.M. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol. Psychiatry 2005, 10(4):332-333.
35. Mehta D., Gonik M., Klengel T., Rex-Haffner M., Menke A., Rubel J., Mercer K.B., Putz B., Bradley B., Holsboer F., et al. Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch. Gen. Psychiatry 2011, 68(9):901-910.
36. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65(9):732-741.
37. Miller A.H., Haroon E., Raison C.L., Felger J.C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety 2013, 30(4):297-306.
38. Miller G.E., Chen E., Sze J., Marin T., Arevalo J.M., Doll R., Ma R., Cole S.W. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 2008, 64(4):266-272.
39. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., Guttridge D., Rhoades C., Shah M., Criswell T., et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. 2006, 24(12):1852-1859.
40. Nanni V., Uher R., Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am. J. Psychiatry 2012, 169(2):141-151.
41. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., Ozaki N., Taguchi T., Tatsumi M., Kamijima K., et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 2004, 13(21):2699-2708.
42. Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012, 18(3):363-374.
43. Oskooilar N., Wilcox C.S., Tong M.L., Grosz D.E. Body mass index and response to antidepressants in depressed research subjects. J. Clin. Psychiatry 2009, 70(11):1609-1610.
44. Pae C.U., Serretti A., Mandelli L., De Ronchi D., Patkar A.A., Jun T.Y., Kim J.J., Lee C.U., Lee S.J., Lee C., et al. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenet. Genomics 2007, 17(1):69-75.
45. Perera T.D., Dwork A.J., Keegan K.A., Thirumangalakudi L., Lipira C.M., Joyce N., Lange C., Higley J.D., Rosoklija G., Hen R., et al. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One 2011, 6(4):e17600.
46. Pico A.R., Kelder T., van Iersel M.P., Hanspers K., Conklin B.R., Evelo C. WikiPathways: pathway editing for the people. PLoS Biol. 2008, 6(7):e184.
47. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27(1):24-31.
48. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70(1):31-41.
49. Rathmell J.C., Fox C.J., Plas D.R., Hammerman P.S., Cinalli R.M., Thompson C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 2003, 23(20):7315-7328.
50. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58(5):445-452.
51. Rhee J., Inoue Y., Yoon J.C., Puigserver P., Fan M., Gonzalez F.J., Spiegelman B.M. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc. Natl. Acad. Sci. USA 2003, 100(7):4012-4017.
52. Rush A.J., Wisniewski S.R., Warden D., Luther J.F., Davis L.L., Fava M., Nierenberg A.A., Trivedi M.H. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch. Gen. Psychiatry 2008, 65(8):870-880.
53. Rustad J.K., Musselman D.L., Nemeroff C.B. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology 2011, 36(9):1276-1286.
54. Shelton R.C., Miller A.H. Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog. Neurobiol. 2010, 91(4):275-299.
55. Shmelkov E., Tang Z., Aifantis I., Statnikov A. Assessing quality and completeness of human transcriptional regulatory pathways on a genome-wide scale. Biol. Direct 2011, 6:15.
56. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132(6):2169-2180.
57. Sluzewska A., Sobieska M., Rybakowski J.K. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997, 35(3):123-127.
58. Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002, 99(10):6567-6572.
59. Torres, M.A., Pace, T.W., Liu, T., Felger, J.C., Mister, D., Doho, G.H., Kohn, J.N., Barsevick, A.M., Long, Q., Miller, A.H., 2013. Predictors of depression in breast cancer patients treated with radiation: Role of prior chemotherapy and nuclear factor kappa B. Cancer. http://dx.doi.org/10.1002/cncr.28003.
60. Trivedi M.H., Rush A.J., Ibrahim H.M., Carmody T.J., Biggs M.M., Suppes T., Crismon M.L., Shores-Wilson K., Toprac M.G., Dennehy E.B., et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 2004, 34(1):73-82.
61. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367(9504):29-35.
62. Wang D.S., Dickson D.W., Malter J.S. Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views. Int. J. Clin. Exp. Pathol. 2008, 1(1):5-18.
63. Winer D.A., Winer S., Shen L., Wadia P.P., Yantha J., Paltser G., Tsui H., Wu P., Davidson M.G., Alonso M.N., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17(5):610-617.
64. Witten D., Tibshirani R., Gu S.G., Fire A., Lui W.O. Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol. 2010, 8:58.
65. Yamagata K., Furuta H., Oda N., Kaisaki P.J., Menzel S., Cox N.J., Fajans S.S., Signorini S., Stoffel M., Bell G.I. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996, 384(6608):458-460.
66. Yin L., Ma H., Ge X., Edwards P.A., Zhang Y. Hepatic hepatocyte nuclear factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis. Arteriosclerosis, thrombosis, and vascular biology 2011, 31(2):328-336.